stockportfolio.pro
Merck & Co., Inc. (MRK)
Healthcare · Drug Manufacturers - General · NYSE
Merck & Co., Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $39.81B | $40.12B | $42.29B | $39.12B | $41.52B | $48.70B | $59.28B | $60.12B | $64.17B | $65.01B |
| Gross profit | $25.78B | $27.21B | $28.79B | $27.11B | $27.90B | $35.08B | $41.87B | $43.99B | $48.98B | $48.63B |
| Net income | $3.92B | $2.39B | $6.22B | $9.84B | $7.07B | $13.05B | $14.52B | $365.00M | $17.12B | $18.25B |
| Net margin | 9.8% | 6.0% | 14.7% | 25.2% | 17.0% | 26.8% | 24.5% | 0.6% | 26.7% | 28.1% |
Source: Merck & Co., Inc. SEC filings (10-K). 19 years of history available in the interactive view.
What growth is priced into MRK stock?
At today's market cap of $295.39B, Merck & Co., Inc. is priced for free-cash-flow growth of about 10.1% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $12.36B from the FY ending 2025-12-31). For comparison, free cash flow actually grew 16.2%/yr over the last five fiscal years and revenue 9.4%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 19 years of Merck & Co., Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track MRK in your portfolio →
Merck & Co., Inc. financial history by metric
About Merck & Co., Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.
Merck & Co., Inc. — frequently asked questions
What is Merck & Co., Inc.'s revenue?
Merck & Co., Inc. (MRK) reported revenue of $65.01B for fiscal year 2025, up 1.3% from the prior year, according to its SEC filings.
Is Merck & Co., Inc. profitable?
Yes. MRK earned net income of $18.25B in fiscal 2025, a net margin of 28.1%.
What is MRK's P/E ratio?
Merck & Co., Inc. trades at a price-to-earnings ratio of about 33.7 based on the latest data in our nightly-refreshed cache.
How fast is Merck & Co., Inc. growing?
MRK's revenue grew at roughly 9.4% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Merck & Co., Inc. have?
As of fiscal year 2025, MRK carried roughly $49.34B in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Merck & Co., Inc.'s gross margin?
MRK's gross margin was 74.8% in fiscal 2025 — gross profit of $48.63B on revenue of $65.01B.
What is Merck & Co., Inc.'s market cap?
Merck & Co., Inc. (MRK) has a market capitalization of about $295.39B, based on the latest data in our nightly-refreshed cache.
When does Merck & Co., Inc.'s fiscal year end?
MRK's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into MRK stock?
At today's market cap of $295.39B, Merck & Co., Inc. is priced for free-cash-flow growth of about 10.1% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $12.36B from the FY ending 2025-12-31). For comparison, free cash flow actually grew 16.2%/yr over the last five fiscal years and revenue 9.4%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from Merck & Co., Inc.'s official SEC filings (10-K and 10-Q), covering 19 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.